S
Steven E. Lipshultz
Researcher at University at Buffalo
Publications - 514
Citations - 65630
Steven E. Lipshultz is an academic researcher from University at Buffalo. The author has contributed to research in topics: Cardiomyopathy & Cardiotoxicity. The author has an hindex of 102, co-authored 505 publications receiving 57200 citations. Previous affiliations of Steven E. Lipshultz include Roswell Park Cancer Institute & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Caffeine and Clinical Outcomes in Premature Neonates.
TL;DR: Caffeine therapy is a significant advance in newborn care, conferring immediate benefits in preterm neonates and studies should help define the appropriate therapeutic window for caffeine treatment along with the mechanisms relating to its beneficial effects on the brain and the lung.
Journal ArticleDOI
Anthracycline cardiotoxicity: the importance of horizontally integrating pre-clinical and clinical research.
TL;DR: Cardiotoxicity is an established complication of cancer therapies; the cardiomyopathy caused by anthracyclines is a classic example; however, some new therapies used in conjunction with anthrACYclines have introduced an assortment of cardiovascular complications.
Journal ArticleDOI
Establishing norms for echocardiographic measurements of cardiovascular structures and function in children
TL;DR: Echocardiography is a leading technology for evaluating cardiovascular structure and function in children, and life-altering decisions are constantly made on the basis of quantitative echococardographic measurements.
Journal ArticleDOI
Energy Drink–Induced Near-Fatal Ventricular Arrhythmia Prevented by an Intracardiac Defibrillator Decades After Operative “Repair” of Tetralogy of Fallot
TL;DR: A 45-year old man who experienced a potentially fatal arrhythmia after consumption of multiple energy drinks and had an automatic implantable cardiac defibrillator placed likely would have died without the AICD.
Journal ArticleDOI
Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group
Lisa M. Kopp,Richard B. Womer,Cindy L. Schwartz,David H. Ebb,Vivian I. Franco,David Hall,Donald A. Barkauskas,Donald A. Barkauskas,Mark Krailo,Mark Krailo,Holcombe E. Grier,Paul A. Meyers,Leonard H. Wexler,Neyssa Marina,Katherine A. Janeway,Richard Gorlick,Mark L. Bernstein,Steven E. Lipshultz +17 more
TL;DR: In this paper, the effect of dexrazoxane in children with sarcoma treated with higher-cumulative-dose doxorubicin is unknown, but the effect is shown to be beneficial.